PubMed:343678 JSONTXT

{"project":"bc5cdr-valid-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":73},"obj":"Disease"},{"id":"T3","span":{"begin":154,"end":165},"obj":"Disease"},{"id":"T4","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T5","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T6","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T7","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T8","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T9","span":{"begin":820,"end":825},"obj":"Chemical"},{"id":"T10","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T11","span":{"begin":927,"end":938},"obj":"Disease"},{"id":"T12","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T13","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-nr-ng-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T4","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T5","span":{"begin":369,"end":404},"obj":"Chemical"},{"id":"T6","span":{"begin":738,"end":759},"obj":"Chemical"},{"id":"T7","span":{"begin":764,"end":804},"obj":"Chemical"},{"id":"T8","span":{"begin":904,"end":925},"obj":"Chemical"},{"id":"T9","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-nr-g-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":80},"obj":"Chemical"},{"id":"T3","span":{"begin":81,"end":89},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":388},"obj":"Chemical"},{"id":"T9","span":{"begin":389,"end":396},"obj":"Chemical"},{"id":"T10","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T11","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T12","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T13","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T14","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T15","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T16","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T17","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":778,"end":786},"obj":"Chemical"},{"id":"T19","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T20","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T21","span":{"begin":904,"end":918},"obj":"Chemical"},{"id":"T22","span":{"begin":927,"end":945},"obj":"Chemical"},{"id":"T23","span":{"begin":946,"end":954},"obj":"Chemical"},{"id":"T24","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T25","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-g-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T3","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T4","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T5","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-ng-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":380},"obj":"Disease"},{"id":"T9","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T10","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T11","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T12","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T13","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T14","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T15","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T16","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T17","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T19","span":{"begin":778,"end":786},"obj":"Chemical"},{"id":"T20","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T21","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T22","span":{"begin":811,"end":815},"obj":"Chemical"},{"id":"T23","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T24","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T25","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T26","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T27","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T28","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-m30","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T10","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T11","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T12","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T13","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T14","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T15","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T16","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T17","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-m20","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T3","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T4","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T5","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-nr-ng","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T4","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T5","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T6","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T7","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T8","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T9","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T10","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T11","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T12","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T13","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T14","span":{"begin":778,"end":786},"obj":"Chemical"},{"id":"T15","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T16","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T17","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T18","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T19","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T20","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gemini-nr-g","denotations":[{"id":"T1","span":{"begin":7,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T9","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T10","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T11","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T12","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T13","span":{"begin":514,"end":528},"obj":"Disease"},{"id":"T14","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T15","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T16","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T17","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T19","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T20","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T21","span":{"begin":889,"end":900},"obj":"Disease"},{"id":"T22","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T23","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T24","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T25","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T26","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T27","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gemini-nr-ng","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T9","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T10","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T11","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T12","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T13","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T14","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T15","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T16","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T17","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T18","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T19","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T20","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T21","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T22","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T23","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gemini-r-g","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T9","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T10","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T11","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T12","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gemini-r-ng","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T9","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T10","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T11","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T12","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T13","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T14","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T15","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T16","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T17","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T19","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T20","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T21","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T22","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T23","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T24","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":73},"obj":"Disease"},{"id":"T3","span":{"begin":154,"end":165},"obj":"Disease"},{"id":"T4","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T5","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T6","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T7","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T8","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T9","span":{"begin":820,"end":825},"obj":"Chemical"},{"id":"T10","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T11","span":{"begin":927,"end":938},"obj":"Disease"},{"id":"T12","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T13","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-g","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T10","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T11","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T12","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T13","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T14","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T15","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T16","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T17","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-ng","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T9","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T10","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T11","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T12","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T13","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T14","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T15","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T16","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T17","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T19","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T20","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T21","span":{"begin":811,"end":815},"obj":"Chemical"},{"id":"T22","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T23","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T24","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T25","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T26","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T27","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-nr-g","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T3","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T4","span":{"begin":628,"end":640},"obj":"Disease"},{"id":"T5","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T6","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-nr-ng","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T9","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T10","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T11","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T12","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T13","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T14","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T15","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T16","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T17","span":{"begin":778,"end":786},"obj":"Chemical"},{"id":"T18","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T19","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T20","span":{"begin":811,"end":815},"obj":"Chemical"},{"id":"T21","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T22","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T23","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T24","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T25","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T26","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-r-ng","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T4","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T5","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T6","span":{"begin":369,"end":396},"obj":"Chemical"},{"id":"T7","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T8","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T10","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T11","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T12","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T13","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T14","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T15","span":{"begin":778,"end":786},"obj":"Chemical"},{"id":"T16","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T17","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T18","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T19","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T20","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gemini-r-m","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T3","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T4","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-m2","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":89},"obj":"Chemical"},{"id":"T3","span":{"begin":154,"end":181},"obj":"Chemical"},{"id":"T4","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T5","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T6","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T7","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T8","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T9","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T10","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T11","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T12","span":{"begin":682,"end":686},"obj":"Chemical"},{"id":"T13","span":{"begin":927,"end":954},"obj":"Chemical"},{"id":"T14","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T15","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T16","span":{"begin":1111,"end":1114},"obj":"Chemical"},{"id":"T17","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-r-g","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":73},"obj":"Disease"},{"id":"T3","span":{"begin":154,"end":165},"obj":"Disease"},{"id":"T4","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T5","span":{"begin":369,"end":380},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-nr-g","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":80},"obj":"Chemical"},{"id":"T3","span":{"begin":81,"end":89},"obj":"Chemical"},{"id":"T4","span":{"begin":154,"end":172},"obj":"Chemical"},{"id":"T5","span":{"begin":183,"end":187},"obj":"Chemical"},{"id":"T6","span":{"begin":193,"end":214},"obj":"Chemical"},{"id":"T7","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T8","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T9","span":{"begin":369,"end":388},"obj":"Chemical"},{"id":"T10","span":{"begin":389,"end":396},"obj":"Chemical"},{"id":"T11","span":{"begin":398,"end":403},"obj":"Chemical"},{"id":"T12","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T13","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T14","span":{"begin":482,"end":485},"obj":"Chemical"},{"id":"T15","span":{"begin":530,"end":538},"obj":"Chemical"},{"id":"T16","span":{"begin":663,"end":666},"obj":"Chemical"},{"id":"T17","span":{"begin":738,"end":752},"obj":"Chemical"},{"id":"T18","span":{"begin":754,"end":758},"obj":"Chemical"},{"id":"T19","span":{"begin":764,"end":773},"obj":"Chemical"},{"id":"T20","span":{"begin":778,"end":786},"obj":"Chemical"},{"id":"T21","span":{"begin":788,"end":793},"obj":"Chemical"},{"id":"T22","span":{"begin":795,"end":803},"obj":"Chemical"},{"id":"T23","span":{"begin":904,"end":909},"obj":"Chemical"},{"id":"T24","span":{"begin":927,"end":945},"obj":"Chemical"},{"id":"T25","span":{"begin":946,"end":954},"obj":"Chemical"},{"id":"T26","span":{"begin":990,"end":993},"obj":"Chemical"},{"id":"T27","span":{"begin":1008,"end":1024},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-deepseek-r-m","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":62,"end":73},"obj":"Disease"},{"id":"T3","span":{"begin":154,"end":165},"obj":"Disease"},{"id":"T4","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T5","span":{"begin":369,"end":380},"obj":"Disease"},{"id":"T6","span":{"begin":422,"end":440},"obj":"Disease"},{"id":"T7","span":{"begin":628,"end":640},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}

{"project":"bc5cdr-valid-gpt-r-m","denotations":[{"id":"T1","span":{"begin":0,"end":16},"obj":"Disease"},{"id":"T2","span":{"begin":321,"end":337},"obj":"Disease"},{"id":"T3","span":{"begin":431,"end":440},"obj":"Disease"},{"id":"T4","span":{"begin":1008,"end":1024},"obj":"Disease"},{"id":"T5","span":{"begin":1129,"end":1145},"obj":"Disease"}],"text":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.\nHepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included."}